Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 29, 2015 10:56 PM ET


Company Overview of Nivalis Therapeutics, Inc.

Company Overview

Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of product candidates for patients with cystic fibrosis (CF). CF is a life-shortening genetic disease. Its lead product candidate is N91115, a small molecule that is in Phase Ib clinical trial, which addresses a defect in cystic fibrosis transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. The company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquartered in Boulder, Colorado.

3122 Sterling Circle

Suite 200

Boulder, CO 80301

United States

Founded in 2007

23 Employees



Key Executives for Nivalis Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 51
Chief Financial Officer and Secretary
Age: 56
Chief Operating Officer
Age: 56
Vice President of Research & Discovery
Age: 52
Vice President of Clinical Research & Development and Medical Director
Age: 62
Compensation as of Fiscal Year 2014.

Nivalis Therapeutics, Inc. Key Developments

N30 Pharmaceuticals, Inc. has Changed its Name to Nivalis Therapeutics, Inc

N30 Pharmaceuticals, Inc. changed its name to Nivalis Therapeutics, Inc.

Nivalis Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Nivalis Therapeutics, Inc. filed its Annual on Feb 13, 2015 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

N30 Pharmaceuticals Appoints R. Michael Carruthers as Chief Financial Officer

N30 Pharmaceuticals, Inc. announced that R. Michael Carruthers has been appointed to the position of chief financial officer (CFO). Mr. Carruthers brings more than 25 years of executive-level financial expertise to N30 Pharma. Most recently, Mr. Carruthers served on Array BioPharma Inc.'s executive team as the CFO, where he executed the company's initial public offering and multiple follow-on equity and debt fund raises. Mr. Carruthers is also experienced in strategic planning and managing organizations through rapid growth, and with transactions and negotiations involving partnering, licensing, drug discovery and clinical development. Prior to joining Array, Mr. Carruthers served as CFO of Sievers Instrument, Inc., and before joining Sievers was the treasurer and controller for the Waukesha division of Dover Corporation. Mr. Carruthers was previously employed as an accountant with Coopers & Lybrand, LLP. Mr. Carruthers received a B.S. in accounting from the University of Colorado and a M.B.A. from the University of Chicago.

Similar Private Companies By Industry

Company Name Region
Innovative Biologics, Inc. United States
Groove Biopharma Corporation United States
Avidia, Inc. United States
AeroGenics, LLC United States
DTI Medical Corp. United States

Recent Private Companies Transactions

Private Placement
November 18, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Nivalis Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at